Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:law
|
| gptkbp:alsoKnownAs |
gptkb:Right_to_Try_Act
|
| gptkbp:alternativeTo |
gptkb:FDA_Expanded_Access_(Compassionate_Use)
|
| gptkbp:appliesTo |
investigational drugs
patients with life-threatening diseases |
| gptkbp:category |
health law
federal law of the United States |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:criticizedFor |
medical ethicists
|
| gptkbp:dateEnacted |
2018-05-30
|
| gptkbp:enactedBy |
gptkb:United_States_Congress
|
| gptkbp:excludes |
FDA approval process
|
| https://www.w3.org/2000/01/rdf-schema#label |
Right to Try law
|
| gptkbp:publicLawNumber |
gptkb:Public_Law_115-176
|
| gptkbp:purpose |
allow terminally ill patients to access experimental treatments
|
| gptkbp:requires |
drug has completed Phase I clinical trials
|
| gptkbp:signedBy |
gptkb:Donald_Trump
|
| gptkbp:sponsor |
gptkb:Senator_Ron_Johnson
|
| gptkbp:subjectOf |
debate over drug efficacy
debate over patient safety |
| gptkbp:supportedBy |
patient advocacy groups
|
| gptkbp:bfsParent |
gptkb:Right_to_Try_Act
|
| gptkbp:bfsLayer |
6
|